Clinical trial · Interventional
Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
Phase I Combined Modality Protocol for Malignant Mesothelioma: Cisplatin & rIFN-alpha-2b Followed by Surgical Resection (Debulking), and Post-Op Concurrent Chemoradiotherapy With Cisplatin, +/- rIFN-alpha-2b
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy, radiation therapy, and interferon alfa may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of cisplatin plus interferon alfa followed by surgery and interferon alfa plus radiation therapy in treating patients with malignant pleural mesothelioma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Mesothelioma | Malignant Mesothelioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin | Drug | Cisplatin | ALIAS |
| radiation therapy | Radiation | — | UNRESOLVED |
| recombinant interferon alfa | Biological | — | UNRESOLVED |
| surgical procedure | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven ipsilateral malignant pleural mesothelioma * No contralateral thoracic or intra-abdominal involvement * No distant metastases PATIENT CHARACTERISTICS: * Age: 18 and over * Performance status: ECOG 0 or 1 * Life expectancy: Not specified * Hematopoietic: * Absolute neutrophil count greater than 2,000/mm3 * Platelet count greater than 100,000/mm3 * No symptomatic anemia requiring transfusion * Hepatic: * Bilirubin less than 2.0 mg/dL * No autoimmune hepatitis * No history of decompensated liver disease; e.g. esophageal varices * Ascites * Albumin at least 2.5 mg/dL * Increasing prothrombin time of at least 2.0 * Renal: Creatinine no greater than 1.5 mg/dL * Cardiovascular: * No symptomatic or debilitating cardiovascular disease, * No concurrent thrombophlebitic or embolic disorders * Pulmonary: * No symptomatic or debilitating pulmonary disease, * Pretreatment diffusion capacity greater than 30% of predicted normal * Projected post-treatment FEV1 at least 1.0 L * Other: * No prior malignancy within 3 years, except nonmelanomatous skin cancer * Carcinoma in situ of the cervix * Ductal carcinoma in situ of the breast * Not pregnant * Fertile patients must use effective contraception * No history of hypersensitivity to interferon or any component of the injection * No uncontrolled diabetes (blood sugars consistently at least 300 mg/dL) * No insulin dependent diabetes mellitus with history of ketoacidosis within 1 year * No psychosis * No uncontrolled thyroid abnormalities * No active infection requiring intravenous antibiotics PRIOR CONCURRENT THERAPY: * Biologic therapy: No prior biologic therapy * Chemotherapy: No prior chemotherapy * Endocrine therapy: Not specified * Radiotherapy: No prior radiotherapy * Surgery: * No prior debulking surgery * No prior chest tube drainage with sclerosis if tumor resectable * Prior thoracentesis allowed
References
Publications (0)
Data not yet available